Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Osteoporosis is currently receiving particular attention as a sequela in survivors of childhood osteosarcoma. The aim of this study was to evaluate bone mineral density (BMD) changes during methotrexate-based chemotherapy in children and adolescents with osteosarcoma. Methods: Nine patients with osteosarcoma were included in this retrospective study and compared with eight healthy controls. BMD of the lumbar spine and unaffected femur neck of patients was serially measured by dual-energy x-ray absorptiometry (DXA) before and just after chemotherapy and compared with controls. Results: Four patients (44%) showed decreased lumbar spine BMD and seven patients (78%) showed decreased femur neck BMD, while all controls showed increased lumbar and femur BMD (P=0.024 and P=0.023). The femur neck BMD z-scores decreased from −0.49±1.14 to −1.63±1.50 (P=0.032). At the end of therapy, five patients (56%) showed femur neck BMD z-scores below –2.0. Conclusion: The bone metabolism is disturbed during therapy in children with osteosarcoma, resulting in a reduced BMD with respect to healthy controls. Since a reduced BMD predisposes to osteoporosis, specific attention and therapeutic interventions should be considered.
Abstract
Purpose: Osteoporosis is currently receiving particular attention as a sequela in survivors of childhood osteosarcoma. The aim of this study was to evaluate bone mineral density (BMD) changes during methotrexate-based chemotherapy in children and adolescents with osteosarcoma. Methods: Nine patients with osteosarcoma were included in this retrospective study and compared with eight healthy controls. BMD of the lumbar spine and unaffected femur neck of patients was serially measured by dual-energy x-ray absorptiometry (DXA) before and just after chemotherapy and compared with controls. Results: Four patients (44%) showed decreased lumbar spine BMD and seven patients (78%) showed decreased femur neck BMD, while all controls showed increased lumbar and femur BMD (P=0.024 and P=0.023). The femur neck BMD z-scores decreased from −0.49±1.14 to −1.63±1.50 (P=0.032). At the end of therapy, five patients (56%) showed femur neck BMD z-scores below –2.0. Conclusion: The bone metabolism is disturbed during therapy in children with osteosarcoma, resulting in a reduced BMD with respect to healthy controls. Since a reduced BMD predisposes to osteoporosis, specific attention and therapeutic interventions should be considered.
참고문헌 (27)
- Cooper C, "Review: developmental origins of osteoporotic fracture", Osteoporos Int, 17, pp.337~347 (2006)
- Mora S, "Establishment of peak bone mass", Endocrinol Metab Clin North Am, 32, pp.39~63 (2003)
- Pfeilschifter J, "Osteoporosis due to cancer treatment:pathogenesis and management", J Clin Oncol, 18, pp.1570~1593 (2000)
- 강민재, "Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management", Korean Journal of Pediatrics, 56(2), pp.60~67 (2013), 대한소아과학회
- "Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, ver. 3.0" (2012)[URL]
- van der Sluis IM, "Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia", J Pediatr, 141, pp.204~210 (2002)
- Halton JM, "Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia", J Bone Miner Res, 11, pp.1774~1783 (1996)
- Luetke A, "Osteosarcoma treatment - where do we stand? A state of the art review", Cancer Treat Rev, 40, pp.523~532 (2014)
- Holzer G, "Bone mineral density in long-term survivors of highly malignant osteosarcoma", J Bone Joint Surg Br, 85, pp.231~237 (2003)
- Lim JS, "Young age at diagnosis, male sex, and decreased lean mass are risk factors of osteoporosis in long-term survivors of osteosarcoma", J Pediatr Hematol Oncol, 35, pp.54~60 (2013)
- Lee JA, "Osteosarcoma developed in the period of maximal growth rate have inferior prognosis", J Pediatr Hematol Oncol, 30, pp.419~424 (2008)
- Lim JS, "Bone mineral density according to age, bone age, and pubertal stages in korean children and adolescents", J Clin Densitom, 13, pp.68~76 (2010)
- Guise TA., "Bone loss and fracture risk associated with cancer therapy", Oncologis, 11, pp.1121~1131 (2006)
- van der Sluis IM, "Osteoporosis in children with cancer", Pediatr Blood Cancer, 50(2Suppl), pp.474~478 (2008)
- Athanassiadou F, "Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment", Pediatr Hematol Oncol, 22, pp.285~289 (2005)
- 이재민, "Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma", Blood Research, 48(2), pp.99~106 (2013), 대한혈액학회
- Wasilewski-Masker K, "Bone mineral density deficits in survivors of childhood cancer: long-term followup guidelines and review of the literature", Pediatrics, 121, pp.e705~e713 (2008)
- Joo NS, "Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density:analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010)", J Bone Miner Res, 28, pp.764~770 (2013)
- Jaffe N, "High-dose methotrexate in osteogenic sarcoma", Natl Cancer Inst Monogr, (56), pp.201~206 (1981)
- Goorin AM, "The Dana Farber Cancer Institute", The children's hospital adjuvant chemotherapy trials for osteosarcoma: three sequential studies, 1985, pp.3, 155~159
- Meyers PA, "Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol", J Clin Oncol, 16, pp.2452~2458 (1998)
- Kim MS, "Time dependency of prognostic factors in patients with stage II osteosarcomas", Clin Orthop Relat Res, 463, pp.157~165 (2007)
- May KP, "The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats", Arthritis Rheum, 37, pp.201~206 (1994)
- Mandel K, "Skeletal morbidity in childhood acute lymphoblastic leukemia", J Clin Oncol, 22, pp.1215~1221 (2004)
- Syed F, "Mechanisms of sex steroid effects on bone", Biochem Biophys Res Commun, 328, pp.688~696 (2005)
- Lajer H, "Cisplatin and hypomagnesemia", Cancer Treat Rev, 25, pp.47~58 (1999)
- Castiglioni S, "Magnesium and osteoporosis: current state of knowledge and future research directions", Nutrients, 5, pp.3022~3033 (2013)